Linkage analysis is performed to assess whether a phenotype of interest-a disease outcome or any measured biomarker level-is transmitted through generations along with a chromosomal segment. Linkage scans are often based on microsatellite markers located at an average distance of a few centimorgans (cMs) from each other, with 1cM corresponding to approximately one million DNA base pairs. Consequently, causal loci can only be mapped to large regions. The analysis is generally performed by a multipoint approach; that is, several consecutive markers are combined together into long-range haplotypes. Thus, the identified loci may represent a single gene with a relatively large effect or several closely linked genes, each with a moderate effect, that together have a large effect. The identified linkage regions are usually refined by association analysis, which aims to detect whether a particular phenotype is more likely to happen when a specific allele is present. Association is performed on very dense maps of biallelic single-nucleotide polymorphisms, tested one by one. In this way, the candidate region is narrowed down and is defined by all single-nucleotide polymorphisms that are in strong linkage disequilibrium (physical correlation) with the one more strongly associated with the investigated phenotype. Park and colleagues 1 (this issue) performed a linkage analysis of the glomerular filtration rate estimated from serum creatinine (eGFR creat ), followed by family-based association testing, conditional to the presence of linkage. This approach has been successfully applied in several other contexts. The family-based association testing prevents spurious association due to population stratification, 2 while the association analysis within predefined linkage regions reduces the risk of false positives by reducing the number of tests performed.
Of the two identified loci, the one on chromosome 9q21 concerns the FERM domain-containing protein 3 (FRMD3) gene. Variants in or near this gene have been previously associated with type 1 diabetic nephropathy (DN) in people of European ancestry, 3 with DN defined by either persistent proteinuria or end-stage renal disease. In a study on African Americans with type 2 diabetes, 4 the association between FRMD3 and DN was confirmed, but only when accounting for the genetic makeup of two other genes: non-muscle myosin heavy chain 9 (MYH9) and apolipoprotein L1 (APOL1) on chromosome 22, which are known to confer high risk of nondiabetic nephropathy. In particular, the strong association was observed only among people lacking specific haplotypes in the MYH9 or APOL1 gene. Additionally, the authors demonstrated that the association between FRMD3 and type 2 DN was related to nephropathy itself and not to diabetes, which could explain why the association was found both in type 1 and in type 2 DN. Now, Park et al. 1 show that the association with FRMD3 is not limited to DN but extends to eGFR creat in a general population, unselected for diabetes or other diseases. The association becomes stronger with adjustment for other renal function determinants such as glucose level, body mass index, and hypertension. These results match very well with previous linkage analyses, in which linkage between the 9q21 locus and eGFR creat was observed to be independent of diabetes status 5 and was replicated in the general population. 6 Taken together, these results suggest that the FRMD3 locus is related to kidney function independently of the major sources of renal insufficiency, that is, diabetes and hypertension. However, some issues await clarification. First, no association between eGFR creat and FRMD3 has been reported so far by any of the large metaanalyses of genome-wide association studies in people of European, African, and Asian ancestry. [7] [8] [9] Is it because stratification for the MYH9/APOL1 risk haplotypes was not considered in those studies? If that is the case, the next hypothesis is that the MYH9/APOL1 risk haplotypes are absent or at least particularly rare in the small Mongolian isolate considered by Park et al. 1 Answering these questions would help clarify the role of both FRMD3 and MYH9/APOL1 gene variants in renal function regulation.
The locus identified on chromosome 15q21 was previously reported to be in linkage with creatinine levels in West Africans with type 2 diabetes 10 and in a European isolated-population study. 11 Within this region, the strongest signal was observed in a locus where many different genes are in strong linkage disequilibrium with each other. A priori, none of them can be excluded from being responsible for the changes in eGFR creat levels. Nevertheless, the obvious candidate seems to be the L-arginine:glycine amidinotransferase (GATM or AGAT) gene. GATM is highly expressed in the kidney and pancreas and is involved in creatine biosynthesis from the beginning of embryonic development. This could explain the large extent of replication across ethnicities. 8, 12 Interestingly, the gene is located in a bridge position between the creatine pathway and the urea cycle (Figure 1) . From this perspective, it is not surprising that the P values at this gene reported by Park et al. 1 are so much smaller than the P values reported before from studies of similar size. In fact, Park et al. estimated the eGFR creat using the six-parameter Modification of Diet in Renal Disease Study equation, which includes both serum creatinine and blood urea nitrogen. Blood urea nitrogen is likely to have played an important role in the reported association, because it not only derives from the urea cycle but is also a sub-product of the creatine pathway, when creatinase synthesizes sarcosine. Thus, the reported result probably reflects the pleiotropic nature of GATM, which is involved in the regulation of both creatinine and blood urea nitrogen. Whether GATM plays a role in renal function regulation seems unlikely, because the association with eGFR creat could not be replicated when glomerular filtration rate was estimated with cystatin C. 12 As demonstrated by the several independent hits reported, and as expected on the basis of the multipoint nature of the linkage analysis, it is likely that the linkage signal on chromosome 15 is due to the joint contribution of several other genes. Among those reported, some attention should be given to the gliomedin (GLDN) gene, which was also associated with serum creatinine in a genome-wide association study on people of Asian ancestry. 9 Another important gene under the linkage peak is the WD repeat-containing protein 72 (WDR72) gene, which was already associated with creatinine, eGFR creat , and blood urea nitrogen in the cited Asian meta-analysis 9 as well as in other ethnicities. WDR72 is not mentioned by Park et al. 1 possibly because it did not reach the strict significance threshold or because of some special genetic structure of this isolated population at that locus.
Going beyond these very interesting results, it is worth reasoning about the role of pedigree-based, isolated-population studies in the search for genetic determinants of complex phenotypes, such as renal function. One advantage of isolated-population studies is the homogeneous environment shared by all the individuals. This homogeneity, which is translated into more homogeneous environmental exposures, can enhance the phenotypic differences that are purely due to a genetic component, thus boosting the association signals by reducing the standard error estimates. In addition, it is anticipated that specific Chronic kidney disease (CKD) continues to be a modern-day epidemic, and it is associated with significant morbidity and mortality. 1 Although there is an abundance of experimental animal studies as well as clinical cross-sectional and longitudinal studies in this field, well-designed and adequately powered randomized controlled trials (RCTs) evaluating specific interventions remain relatively scarce. 2 In this regard, the RCT reported by de Boer et al. 3 (this issue) is certainly a step in the right direction.
CKD and metabolic syndrome
Metabolic syndrome and its individual components, including insulin resistance, are now recognized as independent risk factors for CKD development in diabetic as well as in nondiabetic patients. 4 CKD independently increases insulin resistance, creating a vicious cycle that increases cardiovascular risk. 5 Altered glucose metabolism and reduced tissue sensitivity to insulin have been reported for more than two decades in both early-stage and advanced
